NCT06622057 - D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer | Biotech Hunter

Enrollment

195

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Biliary Tract Cancer (BTC)

Interventions

DRUG

D07001-Softgel Capsules

D07001-softgel capsule is an oral gemcitabine.

DRUG

Placebo

Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)

COMBINATION_PRODUCT

Capecitabine

Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.

Trial Locations (1)

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City